$8.22 -0.18 (-2.14%)
ImageneBio, Inc. Common Stock (IMA)
Company News
OX40 Targeted Therapy Clinical Trials Anti OX40 Antibody Development Market Opportunity Insight 2026
Research highlights emerging OX40/OX40L targeted therapies showing promise in treating inflammatory conditions like asthma and atopic dermatitis, with multiple pharmaceutical companies advancing clinical trials and developing innovative therapeutic approaches.